Literature DB >> 33368138

Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.

Chihiro Koike1, Koji Okudela2, Mai Matsumura1, Hideaki Mitsui1, Takehisa Suzuki1, Hiromasa Arai3, Toshiaki Kataoka1, Yoshihiro Ishikawa4, Shigeaki Umeda1, Yoko Tateishi1, Kenichi Ohashi1.   

Abstract

The present study aimed to discern the molecular alterations involved in the progression of EGFR-mutated lung adenocarcinoma (LADC). We previously demonstrated that the micropapillary (mPAP) element is the most important histological factor for assessing malignant grades in LADCs. Therefore, mPAP and other elements were separately collected from three cases of EGFR-mutated LADC using laser capture microdissection and subjected to a comprehensive mRNA expression analysis. We focused on DYRK2 in this study because its level showed a substantial increase in EGFR-mutated LADCs with mPAP. We also immunohistochemically examined 130 tumors for the expression of DYRK2. The results confirmed a strong expression of DYRK2 in EGFR-mutated LADC with mPAP. Fluorescent in situ hybridization (FISH) analyses targeting the DYRK2 locus revealed frequent gene amplification in EGFR-mutated LADC, specifically occurring in the high-grade components, like mPAP. In summary, the results of this study suggest that DYRK2 overexpression through gene amplification is one of the molecular mechanisms responsible for promoting the progression of EGFR-mutated LADC.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33368138     DOI: 10.14670/HH-18-294

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  30 in total

1.  An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.

Authors:  K Goto; M Satouchi; G Ishii; K Nishio; K Hagiwara; T Mitsudomi; J Whiteley; E Donald; R McCormack; T Todo
Journal:  Ann Oncol       Date:  2012-07-09       Impact factor: 32.976

2.  Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

Authors:  Hideharu Kimura; Kazuo Kasahara; Makoto Kawaishi; Hideo Kunitoh; Tomohide Tamura; Brian Holloway; Kazuto Nishio
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

3.  Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

Authors:  Charles Chuanhai Guo; Vipulkumar Dadhania; Li Zhang; Tadeusz Majewski; Jolanta Bondaruk; Maciej Sykulski; Weronika Wronowska; Anna Gambin; Yan Wang; Shizhen Zhang; Enrique Fuentes-Mattei; Ashish Madhav Kamat; Colin Dinney; Arlene Siefker-Radtke; Woonyoung Choi; Keith A Baggerly; David McConkey; John N Weinstein; Bogdan Czerniak
Journal:  Eur Urol       Date:  2016-03-15       Impact factor: 20.096

4.  Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Hideki Endoh; Hiroyuki Kuwano; Takashi Takahashi; Tetsuya Mitsudomi
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

5.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

Review 7.  Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Authors:  Justin F Gainor; Alice T Shaw
Journal:  Oncologist       Date:  2013-06-28

8.  Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Authors:  Kyuichi Kadota; Jonathan Villena-Vargas; Akihiko Yoshizawa; Noriko Motoi; Camelia S Sima; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

9.  ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.

Authors:  Justin F Gainor; Anna M Varghese; Sai-Hong Ignatius Ou; Sheheryar Kabraji; Mark M Awad; Ryohei Katayama; Amanda Pawlak; Mari Mino-Kenudson; Beow Y Yeap; Gregory J Riely; A John Iafrate; Maria E Arcila; Marc Ladanyi; Jeffrey A Engelman; Dora Dias-Santagata; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2013-05-31       Impact factor: 12.531

10.  CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature.

Authors:  Naoki Kanomata; Junichi Kurebayashi; Yoshikazu Koike; Rin Yamaguchi; Takuya Moriya
Journal:  BMC Cancer       Date:  2019-01-16       Impact factor: 4.430

View more
  1 in total

Review 1.  Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.

Authors:  Mattias F Lindberg; Laurent Meijer
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.